CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study.

IF 4 2区医学 Q2 ONCOLOGY

Translational lung cancer research Pub Date : 2024-08-31 Epub Date: 2024-08-20 DOI:10.21037/tlcr-24-190

Nobutaka Kataoka, Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Takayuki Takeda, Asuka Okada, Shinsuke Shiotsu, Yusuke Chihara, Osamu Hiranuma, Takahiro Yamada, Takahiro Ota, Taishi Harada, Isao Hasegawa, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama

{"title":"CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study.","authors":"Nobutaka Kataoka, Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Takayuki Takeda, Asuka Okada, Shinsuke Shiotsu, Yusuke Chihara, Osamu Hiranuma, Takahiro Yamada, Takahiro Ota, Taishi Harada, Isao Hasegawa, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama","doi":"10.21037/tlcr-24-190","DOIUrl":null,"url":null,"abstract":"Background: Tumor markers such as serum carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1) are utilized for assessing the effectiveness of chemotherapy in non-small cell lung cancer (NSCLC) patients. Yet, it remains uncertain whether these markers can reliably forecast responses to combined chemoimmunotherapy. Our study aimed to examine the significance and effectiveness of these markers in predicting responses among NSCLC patients undergoing combined chemoimmunotherapy.Methods: This two-part observational study involved patients with NSCLC who were treated with combined chemoimmunotherapy in Japanese hospitals. An initial retrospective study of these patients, with serum CEA and CYFRA 21-1 as prognostic factors for combined chemoimmunotherapy outcomes, served as a discovery cohort. Patients in a subsequent prospective study served as a validation cohort, where we assessed the prognostic accuracy of CEA and CYFRA 21-1 cut-off points determined by the discovery cohort.Results: In total, 121 patients treated with combined chemoimmunotherapy were included, with 44 and 77 patients in the discovery and validation cohorts, respectively. Serum CYFRA 21-1 levels >3.0 ng/mL were significantly associated with progression-free survival (PFS) in both the discovery and validation cohorts (P=0.01, P=0.04, respectively). PFS did not differ significantly by CEA levels (P=0.21).Conclusions: After combined chemoimmunotherapy treatment, serum CYFRA 21-1 stands out as a potentially valuable biomarker for predicting the prognosis of NSCLC.","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384485/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-24-190","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tumor markers such as serum carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1) are utilized for assessing the effectiveness of chemotherapy in non-small cell lung cancer (NSCLC) patients. Yet, it remains uncertain whether these markers can reliably forecast responses to combined chemoimmunotherapy. Our study aimed to examine the significance and effectiveness of these markers in predicting responses among NSCLC patients undergoing combined chemoimmunotherapy.

Methods: This two-part observational study involved patients with NSCLC who were treated with combined chemoimmunotherapy in Japanese hospitals. An initial retrospective study of these patients, with serum CEA and CYFRA 21-1 as prognostic factors for combined chemoimmunotherapy outcomes, served as a discovery cohort. Patients in a subsequent prospective study served as a validation cohort, where we assessed the prognostic accuracy of CEA and CYFRA 21-1 cut-off points determined by the discovery cohort.

Results: In total, 121 patients treated with combined chemoimmunotherapy were included, with 44 and 77 patients in the discovery and validation cohorts, respectively. Serum CYFRA 21-1 levels >3.0 ng/mL were significantly associated with progression-free survival (PFS) in both the discovery and validation cohorts (P=0.01, P=0.04, respectively). PFS did not differ significantly by CEA levels (P=0.21).

Conclusions: After combined chemoimmunotherapy treatment, serum CYFRA 21-1 stands out as a potentially valuable biomarker for predicting the prognosis of NSCLC.

查看原文本刊更多论文

CYFRA 21-1 预测晚期非小细胞肺癌患者联合化疗免疫疗法的疗效：一项前瞻性观察研究。

背景：血清癌胚抗原（CEA）和细胞角蛋白片段 19（CYFRA 21-1）等肿瘤标志物被用于评估非小细胞肺癌（NSCLC）患者化疗的效果。然而，这些标记物能否可靠地预测联合化疗免疫疗法的反应仍不确定。我们的研究旨在探讨这些标记物在预测接受联合化疗免疫疗法的非小细胞肺癌患者的反应方面的意义和有效性：这项由两部分组成的观察性研究涉及在日本医院接受联合化疗免疫疗法的 NSCLC 患者。最初的回顾性研究以血清癌胚抗原（CEA）和CYFRA 21-1作为联合化疗免疫治疗结果的预后因素，并以此作为发现队列。随后进行的一项前瞻性研究中的患者作为验证队列，我们对发现队列确定的 CEA 和 CYFRA 21-1 切点的预后准确性进行了评估：结果：共纳入了121名接受联合化疗免疫疗法的患者，其中发现队列和验证队列中分别有44名和77名患者。在发现队列和验证队列中，血清CYFRA 21-1水平>3.0纳克/毫升与无进展生存期（PFS）显著相关（分别为P=0.01和P=0.04）。CEA水平与无进展生存期无明显差异（P=0.21）：结论：联合化疗免疫治疗后，血清CYFRA 21-1可能成为预测NSCLC预后的重要生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational lung cancer research Medicine-Oncology

CiteScore

7.20

自引率

2.50%

发文量

137

期刊介绍： Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.